SCHEMBL4504792

SCHEMBL4504792

CC(C)N(C(=O)CN1CCN(C(=O)OC(C)(C)C)CC1)c1ccc(N/C(=C2\C(=O)Nc3cc(F)ccc32)c2ccccc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CCNT1 O60563 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CDK9 P50750 1/20 0.38
CCNA1 P78396 1/20 0.38
MDM4 O15151 1/20 0.38
MDM2 Q00987 1/20 0.38
MAPK14 Q16539 2/20 0.38
ABCB1 P08183 1/20 0.37
CCKAR P32238 1/20 0.36
CCKBR P32239 1/20 0.36
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35
IDO2 Q6ZQW0 1/20 0.35
F13A1 P00488 1/20 0.35
TGM2 P21980 1/20 0.35
TGM1 P22735 1/20 0.35
CRBN Q96SW2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4504075 0.92 MEN1 (0.40) MEN1KMT2ACCNT1CCNA2CDK2
SCHEMBL4495850 0.92 MEN1 (0.38) MEN1KMT2AMDM4MDM2MAPK14
SCHEMBL2572004 0.91 AAK1 (0.42) MEN1KMT2AMAPK14ABCB1CCKAR
SCHEMBL480509 0.90 ATM (0.41) ALDH1A1MAPTLMNA
SCHEMBL480510 0.90 ATM (0.41) ALDH1A1MAPTLMNA
SCHEMBL4500233 0.87 CCKAR (0.39) CCKARCCKBRALDH1A1MC4RMC1R
SCHEMBL4500228 0.87 CCKAR (0.39) CCKARCCKBRALDH1A1MC4RMC1R
SCHEMBL4487321 0.87 CCNT1 (0.40) MEN1KMT2ACCNT1CCNA2CDK2
SCHEMBL4495286 0.86 IDO1 (0.45) MEN1KMT2ACCNT1CCNA2CDK2
SCHEMBL4493358 0.85 CCNT1 (0.49) MEN1KMT2ACCNT1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR MEN1 1288/4885KMT2A 3530/4885CCNT1 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.